These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 23290819)

  • 1. Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial.
    Lee SY; Park HS; Lee KY; Kim HJ; Jeon YJ; Jang TW; Lee KH; Kim YC; Kim KS; Oh IJ; Kim SY
    Clin Lung Cancer; 2013 May; 14(3):275-82. PubMed ID: 23290819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
    Arrieta O; González-De la Rosa CH; Aréchaga-Ocampo E; Villanueva-Rodríguez G; Cerón-Lizárraga TL; Martínez-Barrera L; Vázquez-Manríquez ME; Ríos-Trejo MA; Alvarez-Avitia MA; Hernández-Pedro N; Rojas-Marín C; De la Garza J
    J Clin Oncol; 2010 Jul; 28(21):3463-71. PubMed ID: 20547984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
    Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
    J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
    Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
    Manegold C; Gravenor D; Woytowitz D; Mezger J; Hirsh V; Albert G; Al-Adhami M; Readett D; Krieg AM; Leichman CG
    J Clin Oncol; 2008 Aug; 26(24):3979-86. PubMed ID: 18711188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
    J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
    Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
    Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC; Evans WK
    Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
    Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M
    BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.
    Shi M; Gu A; Tu H; Huang C; Wang H; Yu Z; Wang X; Cao L; Shu Y; Wang H; Yang R; Li X; Chang J; Hu Y; Shen P; Hu Y; Guo Z; Tao M; Zhang Y; Liu X; Sun Q; Zhang X; Jiang Z; Zhao J; Chen F; Yu H; Zhang W; Sun J; Li D; Zhou J; Han B; Wu YL
    Ann Oncol; 2021 Jan; 32(1):85-96. PubMed ID: 33130217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.